Bone Health Technologies Receives $5M in Funding for Osteopenia Care

Bone Health Technologies (BHT) has closed its recent round of funding raising $5 Million. The company received funds from Esplanade Ventures, Seitz, and Berkely Catalyst Fund investment firms, as well as from Terumo Medical technology provider. 
 
BHT appointed Ella Seitz from Esplanade Ventures and Yushin Yazaki from Terumo board observers. 
 
Funds will go towards BHT’s mission to reshape bone health for postmenopausal women by funding the last stages of development of the Osteoboost vibration wearable device. This round of funding closed in time for de novo FDA clearance. 
 
Osteoboost is a smart device that is worn as a belt around the hips. It has been clinically proven to protect against the bone strength and bone density loss common with menopause. Precision vibration stimulates the natural mechanism of bone regeneration, which reduces the risk of progression from osteopenia to osteoporosis.
 
In trials, Osteoboost significantly slowed the loss of bone density and also showed a user adherence rate that exceeded 80% with zero serious adverse events. The device is expected to launch later this year. 
 
BHT is finalizing manufacturing and distribution logistics for the first public release. Osteoboost is the first and only non-pharmaceutical FDA-cleared prescription device for osteopenia and osteoporosis.
 
Bone Health Technologies CEO, Laura Yecies commented: “Bringing a breakthrough, de novo, prescription medical device to market is a challenging road that requires patience and perseverance. We chose to validate the science behind Osteoboost through a rigorous clinical trial so that postmenopausal women and their physicians could have confidence in our data. The FDA clearance was the last major external hurdle, and now our focus shifts to the launch later this year. We’re thankful for our early investors who believed in our vision and our new investors who seized on the clinical data and recognized the impact we can have for women around the world.”
 
“Osteopenia is a serious condition that affects 1 in 6 women in North America, and we believe that Osteoboost, as the first FDA-cleared noninvasive wearable device, can make a substantial improvement in the lives of millions of women,” said Ella Seitz, Partner at Esplanade Ventures, a new investor in Bone Health Technologies. “We’re excited for the future of the company and are honored to support Osteoboost’s journey to solving a critical chronic condition for women.”